TrialsgrambetaRCTs are beautiful

OPAL-HK

2015

Patiromer in Patients with CKD and Hyperkalaemia on RAAS Inhibitors

In 243 patients with CKD and hyperkalaemia on RAAS inhibitors, patiromer lowered serum potassium and recurrent hyperkalaemia compared with placebo withdrawal.

Result

Change in serum potassium; recurrent hyperkalaemia
Absolute difference
45 points
NNT
3

Absolute difference and NNT are derived from the event rates.

Also reported: Potassium −1.01 mmol/L (p<0.001);

Original publication
Subtopic
Hyperkalaemia
Design
Single-blind, two-phase trial with randomised withdrawal
Relevance
Supporting: context rather than must-know.
Source
Weir MR, et al. N Engl J Med. 2015;372(3):211-221.doi 10.1056/NEJMoa1410853

Discussion & critique

Enabled continuation of RAAS inhibitors despite hyperkalaemia; led to approval of patiromer.

Discussed in podcasts